1. Introduction {#sec1}
===============

The global population aged \>60 years is increasing continuously now \[[@B1]--[@B3]\], the population aged \>60 years is expected to reach 2 billion by the year of 2050 \[[@B2]\]. Aging is natural and will usually lead to physiological changes that compromise the physical, mental, and functional abilities \[[@B4]\]. Elderly population need to be cared for specially and individually due to increased mobility and comorbidity. Diseases features and risk stratification of elderly acute coronary syndrome (ACS) patients might therefore differ from younger patients. ACS is a critical clinical manifestation referring to a wide spectrum of clinical presentations including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina \[[@B5], [@B6]\]. As expected, the prevalence of ACS is significantly associated with aging \[[@B7]\], and the outcome of elderly patients with ACS is also worse in this patient group as compared to younger patients with ACS \[[@B8]\]. In fact, almost one out of two patients hospitalized for ACS is \>75 years of age \[[@B9]\]. Despite the application of various risk stratification schemes in patients with ACS \[[@B10]--[@B13]\], risk stratification for elderly ACS patients remains challenging due to the lack of sufficient data and reports.

Substantial evidence suggests that serum uric acid (sUA), as the end product of purine metabolism, is an independent biomarker capable of predicting morbidity and mortality in patients with a variety of cardiovascular diseases (CVD) \[[@B14]\], as well as in healthy young and middle-aged adults \[[@B15]\]. The 2018 expert consensus for the diagnosis and treatment of the patient with hyperuricemia \[[@B16]\] highlights the importance of monitoring sUA levels in patients with hyperuricemia and high CV risk \[[@B14], [@B17]\].

Currently available data are less conclusive regarding the role of sUA as an independent risk factor in elderly patients with ACS. Notably, sex-related disparities in this population remain largely unknown \[[@B18]\]. Therefore, this study aimed to investigate the association between hyperuricemia and 1-year all-cause mortality in elderly patients with ACS, as well as the sex-related differences.

2. Methods {#sec2}
==========

2.1. Study Design and Patients {#sec2.1}
------------------------------

This was a retrospective cohort study with 711 patients aged ≥75 years and hospitalized in our center for ACS between January 2013 and December 2017. To ensure exhaustive data collection, only patients who were initially admitted to our center were included; those transferred from other centers were not included. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected by prior approval from the human research committee of our institution. The need for individual consent was waived by the committee.

2.2. Grouping and Definitions {#sec2.2}
-----------------------------

The study population was divided into two groups according to presence or absence of hyperuricemia. Hyperuricemia was defined as sUA levels of \>416 *μ*mol/l (\>7 mg/dl) in men and \>357 *μ*mol/l (\>6 mg/dl) in women \[[@B18]\].

ACS diagnosis was made according to the standard definitions of the American College of Cardiology \[[@B5], [@B19]\]. In the present study, severe heart failure referred to Killip class III-IV or New York Heart Association (NYHA) class III-IV. Ventricular tachycardia (VT) was defined as more than 5 beats monitored by 24-hour Holter electrocardiogram (ECG).

2.3. Data Collection {#sec2.3}
--------------------

The following information was collected: body weight and height during hospitalization and calculated body mass index (BMI), diabetes, atrial fibrillation (AF), chronic kidney disease, history of chest pain, history of CVD treatment, smoking, laboratory parameters, hospital stay, demographic characteristics, medication, and in-hospital management and events. sUA levels were routinely measured after an overnight fast from peripheral venous blood samples within the first 24--48 h of hospitalization. The following biochemical parameters were also obtained: hemoglobin, total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, and glycated hemoglobin A1C (HbA1c).

2.4. Follow-Up {#sec2.4}
--------------

In-hospital outcomes were ascertained by hospital chart review. After discharge, participant follow-up was carried out by means of outpatient visits, telephone calls up to one year.

2.5. Statistical Analysis {#sec2.5}
-------------------------

SPSS 23.0 (IBM, Armonk, NY, USA) was used for statistical analysis. Continuous variables are presented as means ± standard deviation, or as median and interquartile range according to their distribution, as determined by the Kolmogorov-Smirnov test; comparisons between groups were performed with the Student\'s *t*-test or nonparametric tests, as appropriate. Categorical variables are reported as percentage and compared with the chi-square test. Multivariable logistic regression models were used to assess the relationship between risk factors and all-cause mortality. To investigate the possible risk factors for mortality in our study, we first investigated the factors of mortality with univariable analyses based on the clinical characteristics. Multivariable logistic regression analysis was applied with the risk factors defined by univariable analyses with *P* \< 0.05. Estimates of odds ratios (ORs) with their 95% confidence intervals (CIs) were reported. *P* values \<0.05 were considered statistically significant.

3. Results {#sec3}
==========

3.1. Characteristics of the Patients {#sec3.1}
------------------------------------

A total of 711 patients were included in the analysis (438 men and 273 women). The sUA concentrations ranged from 107.4 to 942.1 *μ*mol/l (mean ± SD, 369.1 ± 114.6 *μ*mol/l). sUA levels were significantly higher in males than in females (381.4 ± 110.1 vs. 349.2 ± 119.1 *μ*mol/l; *P* \< 0.001). There were 182 (25.8%) STEMI and 529 (74.2%) NSTEMI patients; prevalence of hyperuricemia was similar between the two groups (34.1% vs. 35.7%).

3.2. Characteristics of the Patients according to sUA {#sec3.2}
-----------------------------------------------------

There were 251 (35.3%) patients in the hyperuricemia group and 460 (64.7%) patients in the normal sUA group. The characteristics of each group are listed in [Table 1](#tab1){ref-type="table"}. Body mass index (BMI), prevalence of hypertension, previous chest pain, previous percutaneous coronary intervention (PCI), and stroke were similar between the two groups. The incidence of hypertension (80.5% vs. 72.6%, *P*=0.020), AF (16.2% vs. 9.5%, *P*=0.008), and severe heart function (61.0% vs. 44.2%, *P* \< 0.001) were significantly higher in patients with hyperuricemia than in patients with normal sUA.

The clinical features at admission are shown in [Table 2](#tab2){ref-type="table"}. Hemoglobin (119.3 ± 19.2 vs. 113.9 ± 21.6 g/l, *P*=0.001) and HDL-cholesterol (1.1 ± 0.3 vs. 1.0 ± 0.3 mmol/L, *P*=0.001) were significantly lower, whereas creatinine levels (138.0 ± 106.8 vs. 96.6 ± 68.1 *μ*mol/l, *P* \< 0.001) and NT-proBNP (887.3 \[290.0--2656.2\] vs. 1704.0 \[536.6--5077.2\], *P* \< 0.001) were significantly higher in the hyperuricemia group than in normal sUA group.

In-hospital management information is shown in Supplemental [](#supplementary-material-1){ref-type="supplementary-material"}. Medication was similar between the two groups, except that aspirin (88.6% vs. 78.5%, *P* \< 0.001) and diuretics (44.1% vs. 55.9%, *P*=0.003) were used more often in the hyperuricemia group than in the non-hyperuricemia group.

3.3. In-Hospital Events and 1-Year Outcomes {#sec3.3}
-------------------------------------------

In-hospital events are shown in [Table 3](#tab3){ref-type="table"}. There were no significant differences in severe heart failure (15.0% vs. 20.8%, *P*=0.053), bleeding (7.5% vs. 11.1%, *P*=0.113), stroke (1.3% vs. 0.4%, *P*=0.244), and death (3.4% vs. 5.8%, *P*=0.334) between the hyperuricemia and non-hyperuricemia groups, whereas the frequency of VT (11.1% vs. 6.8%, *P*=0.040) was significantly higher in the hyperuricemia group than in the non-hyperuricemia group. Hyperuricemia is related to increased risk of in-hospital VT (unadjusted OR = 1.799, 95% CI 1.050--3.081, *P*=0.033). Besides, hyperuricemia is an independent factor associated with the appearance of AF (OR = 2.118, 95% CI 1.126--3.985, *P*=0.020) after adjustment for confounding variables including age, sex, BMI, current smoking, hypertension, diabetes mellitus, PCI or CABG history, CKD ≥ 3, stroke, ACS type, and severe heart failure. A total of 135 patients (19.0%) died during 1-year follow-up, and the all-cause mortality rate was significantly higher in patients with hyperuricemia than in patients with normal sUA (23.1% vs. 16.7%, *P*=0.039). Patients with hyperuricemia had significantly higher unadjusted hazard of death (unadjusted OR = 1.512, 95% CI 1.028--2.225, *P*=0.036) than patients with normal sUA group. Rehospitalization, revascularization, stroke, and bleeding after discharge were similar between the two groups.

3.4. Characteristics of the Patients according to Sex {#sec3.4}
-----------------------------------------------------

Sex-related disparities are shown in [Table 4](#tab4){ref-type="table"}. The prevalence of hyperuricemia was significantly higher in females than in males (39.9% vs. 32.4%, *P*=0.042). Female patients had higher frequencies of diabetes mellitus (35.2% vs. 26.5%, *P*=0.014) and NSTE-ACS (79.5% vs. 72.1%, *P*=0.028); lower frequencies of STEMI (20.5% vs. 26.9%, *P*=0.028) and smoking (5.4% vs. 56.5%, *P* \< 0.001); higher frequency of severe heart failure on admission (56.8% vs. 46.0%, *P*=0.005); higher total cholesterol (4.1 ± 1.0 vs. 3.8 ± 0.9 mmol/l, *P* \< 0.001), HDL-C (1.1 ± 0.3 vs. 1.0 ± 0.3 mmol/L, *P*=0.002), LDL-C (2.4 ± 0.9 vs. 2.2 ± 0.8 mmol/L, *P*=0.002), platelets (202.9 ± 64.9 vs. 174.3 ± 61.4 × 10^9^/L, *P* \< 0.001), and HbA1c (median, 6.7% vs. 6.1%, *P*=0.005); and lower hemoglobin (110.4 ± 18.3 vs. 121.8 ± 20.2 g/L, *P* \< 0.001), alanine aminotransferase (ALT) (median, 17.5 vs. 19.9 U/L, *P*=0.012), creatinine (89.9 ± 54.1 vs. 124.4 ± 98.6 *μ*mol/L, *P* \< 0.001), and sUA (349.2 ± 119.1 vs. 381.4 ± 110.1 *μ*mol/L, *P* \< 0.001) than male patients. The in-hospital mortality rate was similar (3.5% vs. 4.4%, *P*=0.693), but male patients had higher 1-year all-cause mortality (21.7% vs. 14.7%, *P*=0.020). Although patients with hyperuricemia had more severe heart failure on admission (66.1% vs. 50.6%, *P*=0.012; 57.0% vs. 40.7%, *P*=0.012, respectively) and higher creatine (111.1 ± 69.2 vs. 76.0 ± 35.3 *μ*mol/L, *P* \< 0.001; 158.3 ± 124.4 vs. 108.0 ± 78.5 *μ*mol/L, *P* \< 0.001, respectively) and sUA (462.0 ± 101.3 vs. 274.4 ± 52.0 *μ*mol/L, *P* \< 0.001; 504.1 ± 84.3 vs. 322.6 ± 61.9 *μ*mol/L, *P* \< 0.001, respectively) than those without hyperuricemia in female and male population, respectively, female patients with hyperuricemia had a higher frequency of CKD ≥ 3 (9.2% vs. 1.8%, *P*=0.005), lower EF value (51.6 ± 11.7 vs. 55 ± 9.2%, *P*=0.009), and higher 1-year all-cause mortality (22.0% vs. 9.8%, *P*=0.005) than those without hyperuricemia, but mortality was similar in male patients with or without hyperuricemia.

3.5. Multivariable Analyses {#sec3.5}
---------------------------

We examined the independent determinants of 1-year all-cause mortality. As shown in Supplemental [](#supplementary-material-1){ref-type="supplementary-material"}, female patients with hyperuricemia had significantly higher unadjusted odds of death (unadjusted OR = 2.612, 95% CI 1.315--5.189, *P*=0.006) than female patients with normal sUA. Similar results were observed (OR = 2.438, 95% CI 1.215--4.894, *P*=0.012) after adjusting for age (Model 1). The same associations were observed in model 2 (OR = 2.643, 95% CI 1.092--6.400, *P*=0.031) after adjustment for age, BMI, current smoking, hypertension, and diabetes mellitus and in model 3 (OR = 2.539, 95% CI 1.001--6.453, *P*=0.050) after adjustment for age, BMI, current smoking, PCI or CABG history, hypertension, diabetes mellitus, CKD ≥ 3, and stroke. The multivariable analysis showed that hyperuricemia was not an independent risk factor of 1-year all-cause mortality for male patients and for the total cohort (OR = 0.931, 95% CI 0.466--1.858, *P*=0.839; OR = 1.326, 95% CI 0.773--2.273, *P*=0.305, respectively).

4. Discussion {#sec4}
=============

Hyperuricemia is a risk factor for CVDs, but the impact of hyperuricemia and sex-related disparities are not fully clear in elderly patients with ACS. Therefore, this study aimed to investigate the association between hyperuricemia and outcome in elderly patients with ACS. The results suggest that patients with hyperuricemia have higher in-hospital events and 1-year all-cause mortality compared with those without hyperuricemia. Importantly, hyperuricemia is an independent risk factor for one-year all-cause mortality after discharge in elderly female patients with ACS, but not in elderly male patients with ACS.

CVDs are the leading causes of death worldwide \[[@B20]\]. The high mortality in elderly patients with ACS \[[@B1], [@B8]\] justifies the cumulative risk factors, which might result in poor outcome in this patient population. The present study showed a rate of 19.0% for 1-year all-cause mortality in elderly patients with ACS, which is consistent with a previous report \[[@B21]\]. A large body of evidence indicates that hyperuricemia is an emerging CVD risk factor \[[@B22], [@B23]\], besides traditional risk factors for CVD. The results of the present study showed that hyperuricemia is associated with the female sex, arterial hypertension, AF, lower HDL-cholesterol, elevated serum creatinine, and in-hospital cardiac complications. It is likely that the higher in-hospital event and one-year all-cause mortality rates after discharge are the consequences of the more frequent clustering of these risk factors, and hyperuricemia might thus be viewed as a surrogate risk factor in elderly ACS patients. The multivariable analyses showed that hyperuricemia is an independent determinant of one-year all-cause mortality in female ACS patients, but not in males or in the whole cohort after adjustment for age, BMI, current smoking, PCI or CABG history, hypertension, diabetes mellitus, CKD ≥ 3, and stroke, as supported by previous studies \[[@B24]--[@B27]\]. A previous report from a large Chinese cohort showed that the prevalence of hyperuricemia was 42.6% in men and 23.4% in women \[[@B18]\]; we found that the prevalence of hyperuricemia is even higher in elderly female patients with ACS than in their male counterparts. This pattern confirms the presence of sex-specific differences in elderly patients with ACS in terms of hyperuricemia. This discrepancy could be attributed to menopausal women having higher sUA levels than premenopausal women \[[@B28]\]. Women with ACS, especially at age ≥75, have been described as being sicker than their male counterparts \[[@B29]\]. Similarly, our data also indicate that elderly female patients had more risk factors for CVD, including diabetes mellitus, hypertension, and dyslipidemia. Nevertheless, male patients had worse 1-year outcomes compared with those of women. The possible reason might be that male elderly ACS patients have other special risk factors, such as higher frequencies of STEMI, current smoking, and worse renal function, which may influence the 1-year all-cause mortality. It was shown that the prevalence of hyperuricemia in general population was 21.4% (21.2% for men and 21.6% for women) according to the United States National Health and Nutrition Examination Survey (NHANES) study \[[@B30]\]. It was also shown that the prevalence of hyperuricemia increased with aging in male and female (14.2% at age \<30, 20.1% at age 31--40, 22.9% at age 41--50, 22.3% at age 51--60, 23.3% at age 61--70, and 24.1% at age \>70 in men; 2.8% at age\<30, 3.5% at age 31--40, 6.6% at age 41--50, 14.7% at age 51--60, 16.8% at age 61--70, and 23.4% at age \>70 in women) \[[@B31], [@B32]\]. Our study showed that hyperuricemia served as an independent risk factor in elderly female patients with ACS, implicating the importance of monitoring sUA levels in elderly female ACS patients. Future studies are warranted to verify the prognostic importance of hyperuricemia in ACS patients with various ages and sexes. Moreover, it is of importance to observe that more intensive care, including targeting blood uric acid levels on outcome among elderly female ACS patients, is required.

NHANES III trial showed an increased risk of all-cause death and cardiac death in patients with increased sUA levels, and the association remained significant even after adjustment for different factors including demography and comorbidities \[[@B33]\]. On the other hand, our study showed that hyperuricemia was not associated with in-hospital death and 1-year death in elderly ACS patients. The reason for these discrepancies remains elusive. Although hyperuricemia is a risk factor for 1-year all-cause mortality in the present study, we failed to confirm the independent association between hyperuricemia and 1-year all-cause mortality after adjustment for age and other risk factors, suggesting that, in elderly ACS patients, other comorbidities might serve as more important causes of death than hyperuricemia. Notably, few studies have clarified the relationship between hyperuricemia and sex-specific differences in the outcomes of elderly patients with ACS. Our data indicated that female patients with hyperuricemia have higher frequency of CKD ≥ 3, lower EF value, and higher 1-year all-cause mortality than those without hyperuricemia, but this is not observed in males. Importantly, hyperuricemia was associated with an increased risk of 1-year all-cause mortality in elderly women independently of traditional CVD risk factors, but this similar association was not observed in men and in the total population. These findings suggest that hyperuricemia is associated with 1-year all-cause mortality more strongly in women than in men with ACS. A previous study reported that changes in sUA levels in menopausal women is associated with sex hormones \[[@B34]\], thereby sex hormones may partly explain the different risk of hyperuricemia in males and females. Given that the mechanisms behind these sex-specific differences in ACS remain unclear, the representation of women in clinical CVD trials needs to be increased.

The mortality rate was higher in men than in women, which is consistent with the general CVD mortality pattern observed between men and women \[[@B3], [@B20], [@B29]\]. Our findings indicate that, despite lower 1-year mortality among elderly female ACS patients as compared to elderly male ACS patients, hyperuricemia is still considered as an independent risk factor of one-year mortality in elderly female patients, and future studies are warranted to see if more intensive care including therapy targeting hyperuricemia could further reduce the one-year mortality for elderly female ACS patients. Besides, lifestyle habits may also play a role in this difference in mortality. Indeed, in the present study, men had a higher frequency of current smoking than women (57% vs. 5%), which is consistent with the pattern observed in the Chinese population \[[@B35]\]. Smoking is a well-known risk factor for all-cause and CVD death \[[@B35]\]. In addition, men had a higher frequency of STEMI, while women had a higher frequency of severe heart failure. Although the difference was small (but significant), women had higher levels of total, LDL-C and HDL-C than men, but the higher levels of HDL-C probably counteracted the higher LDL-C levels, but this will have to be verified more specifically. Recent evidence suggests that diabetes has a more significant impact on CVD mortality in women than in men \[[@B36]\], but in the present study, mortality in women was lower than in men despite the frequency of diabetes being higher in women; this will have to be investigated.

Lately, a considerable number of reports associating elevated sUA with cardiac rhythm disorders (such as AF) have been published \[[@B37], [@B38]\]. In the present study, the result indicated that hyperuricemia was an independent factor associated with the frequency of AF (OR = 2.118, 95% CI 1.126--3.985, *P*=0.020) after adjustment for confounding variables. Gang Huang et al. \[[@B39]\] investigated hyperuricemia and the risk of AF in the very elderly community and found that participants with hyperuricemia had a higher risk of suffering from AF in very elderly Chinese. Leonardo Tamariz et al. \[[@B40]\] identified 1,085 cases of incident AF. In Cox proportional hazards models adjusted for age, gender, race, center, education, and traditional risk factors at baseline, the hazard ratio of AF associated with a SD increment in sUA was 1.16 (95% confidence interval 1.06 to 1.26). These results indicated that elevated sUA is associated with a greater risk of AF. It is generally accepted that both inflammatory-dependent and -independent mechanisms might play a role in rhythm disorders \[[@B41], [@B42]\]. Elevated concentrations of sUA via xanthine oxidase system activation are related to the generation of oxidative stress and inflammatory mediators \[[@B16]\]. Oxidative stress promotes calcium overload and decreases sodium channels, resulting in electrical remodeling \[[@B43]\]. Proinflammatory molecules induced by oxidative injury are also increased \[[@B44]\]. At the same time, structural remodeling may be mediated by fibroblasts \[[@B43]\]. Subsequently, electrical and structural remodeling may lead to AF \[[@B45]\]. Regarding the association between increased sUA levels and ventricular arrhythmias, the evidence is sparse. The present study strongly suggests that patients with hyperuricemia had higher odds than those with normal sUA according to the univariable logistic regression analyses, and this association was lost after adjusting for other confounders. A small observational study of individuals with ECG evidence of hypertrophy divided into two groups based on whether VT was detected or not on a 24-h ECG recording, demonstrated that sUA was an independent factor associated with the appearance of VT \[[@B46]\], but one should keep in mind that arrhythmia has a complex pathophysiologic background. The limited available data only explain the possible relationship and conceptual framework, and additional research may be needed to clarify the underlying mechanisms.

4.1. Limitations {#sec4.1}
----------------

This study had some limitations. First, this is a single center experience and the number of patients was relatively small when considering the high incidence of ACS. Therefore, we set a strict standard for the selection of potential variables (*P* \< 0.05) for the multivariable logistic analysis, and we might have missed some factors. Besides, the observational study design allows determining only associations and not causality; the mechanisms behind the results obtained require further investigation. Finally, STEMI and NSTE-ACS patients are quite heterogeneous regarding symptoms and outcomes, yet these patients were not analyzed separately in this study.

5. Conclusion {#sec5}
=============

Hyperuricemia is associated with in-hospital events and 1-year all-cause mortality, and it is an independent risk factor for 1-year all-cause mortality after discharge in elderly female patients with ACS. Monitoring sUA levels would be helpful to clinicians treating these elderly patients suffering from hyperuricemia and ACS.
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Additional Points
=================

Elderly ACS patients with hyperuricemia have higher in-hospital events and 1-year all-cause mortality compared with those without hyperuricemia. Hyperuricemia is an independent risk factor for one-year all-cause mortality after discharge in elderly female patients with ACS, but not in elderly male patients with ACS.
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###### 

The supplementary materials contain two tables. In-hospital management information is shown in Supplemental Table 1, and the independent determinants of 1-year all-cause mortality are shown in Supplemental Table 2. And the supplementary Excel file is the datasheet used for the statistical analysis.

###### 

Click here for additional data file.

###### 

Baseline characteristics of patients according to sUA levels.

  Parameters                            sUA normal (*n* = 460)   Hyperuricemia (*n* = 251)   *P*
  ------------------------------------- ------------------------ --------------------------- ---------
  *Demographics and medical history*                                                         
  Age, years (median, IQR)              78 (76--80)              78 (76--81)                 0.308
  Female sex, *n* (%)                   164 (35.7)               109 (43.4)                  0.042
  Body mass index (median, IQR)         22.8 (20.8--25.0)        23.4 (20.8--26.3)           0.101
  Diabetes mellitus, *n* (%)            138 (30.0)               74 (29.5)                   0.885
  Hypertension, *n* (%)                 334 (72.6)               202 (80.5)                  0.020
  Atrial fibrillation, *n* (%)          43 (9.5)                 40 (16.2)                   0.008
  CKD ≥ 3                               17 (3.7)                 22 (8.8)                    0.005
  Stroke, *n* (%)                       70 (15.5)                33 (13.5)                   0.481
  Previous chest pain, *n* (%)          299 (65.9)               168 (68.3)                  0.514
  Previous PCI, *n* (%)                 82 (18.1)                32 (13.0)                   0.082
  Previous CABG, *n* (%)                9 (2.0)                  4 (1.6)                     0.739
  Current smoking, *n* (%)              171 (38.5)               82 (34.2)                   0.261
                                                                                             
  *Examination findings*                                                                     
  SBP, mmHg (median, IQR)               134 (117--152)           132 (118--152)              0.520
  DBP, mmHg (median, IQR)               72 (65--81)              71 (64--80)                 0.184
  Heart rate, beats/min (median, IQR)   75 (67--84)              76 (68--86)                 0.158
                                                                                             
  *Clinical presentation*                                                                    
  Severe heart failure, *n* (%)         203 (44.2)               153 (61.0)                  \<0.001
  STEMI, *n* (%)                        120 (26.1)               62 (24.7)                   0.686
  NSTE-ACS, *n* (%)                     340 (73.9)               189 (75.3)                  0.686

sUA: serum uric acid; IQR: interquartile range; CKD: chronic kidney disease; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; SBP: systolic blood pressure; DBP: diastolic blood pressure; STEMI: ST-elevated myocardial infarction; NSTE-ACS: non-ST-elevation acute coronary syndrome.

###### 

Clinical data on admission of patients according to sUA levels.

  Clinical data                           sUA normal (*n* = 460)   Hyperuricemia (*n* = 251)   *P*
  --------------------------------------- ------------------------ --------------------------- ---------
  WBC, 10^9^/L (mean ± SD)                7.2 ± 3.2                7.5 ± 3.2                   0.252
  Hemoglobin, g/L (mean ± SD)             119.3 ± 19.2             113.9 ± 21.6                0.001
  Platelets, 10^9^/L (mean ± SD)          188.7 ± 64.2             179.0 ± 64.0                0.058
  Fasting glucose, mmol/l (median, IQR)   5.9 (4.8--7.6)           5.6 (4.8--6.7)              0.284
  HbA1C, % (median, IQR)                  6.3 (5.7--6.9)           6.1 (5.6--6.7)              0.313
  ALT, U/l (median, IQR)                  18.8 (12.8--31.8)        18.8 (12.7--33.3)           0.948
  AST, U/l (median, IQR)                  22.9 (17.3--53.2)        22.3 (18.1--37.0)           0.955
  Albumin, g/l (mean ± SD)                35.1 ± 4.0               35.0 ± 4.6                  0.688
  Triglycerides, mmol/l (mean ± SD)       1.6 ± 4.1                1.6 ± 1.1                   0.901
  Total cholesterol, mmol/l (mean ± SD)   3.9 ± 0.9                3.9 ± 1.1                   0.365
  HDL-cholesterol, mmol/l (mean ± SD)     1.1 ± 0.3                1.0 ± 0.3                   0.019
  LDL-cholesterol, mmol/l (mean ± SD)     2.3 ± 0.8                2.33 ± 0.9                  0.211
  Creatinine, *μ*mol/l (mean ± SD)        96.6 ± 68.1              138.0 ± 106.8               \<0.001
  PT, *s* (mean ± SD)                     13.3 ± 2.5               14.1 ± 4.7                  0.117
  APTT, *s* (mean ± SD)                   42.3 ± 21.9              36.8 ± 11.9                 0.101
  CK, U/l (mean ± SD)                     350.8 ± 714.9            294.6 ± 524.1               0.561
  CK-Mb, U/l (mean ± SD)                  42.0 ± 102.8             38.4 ± 104.7                0.681
  TnT, pg/ml (median, IQR)                20.1 (11.3--1268.5)      46.7 (12.2--1418.3)         0.365
  hs-CRP, mg/l (median, IQR)              4.2 (1.2--23.2)          7.0 (1.8--20.5)             0.173
  NT-proBNP, pg/ml (median, IQR)          887.3 (290.0--2656.2)    1704.0 (536.6--5077.2)      \<0.001
  EF, % (mean ± SD)                       54 ± 10.1                52 ± 11.8                   0.072

sUA: serum uric acid; WBC: white blood cells; HbA1c: glycated hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; HDL: high-density lipoprotein; LDL: low-density lipoprotein; PT: prothrombin time; APTT: activated prothrombin time; CK: creatine kinase; CK-Mb: creatine kinase Mb chain; TnT: troponin *T*; hs-CRP: high-sensitivity C-reactive protein; NR-proBNP: N-terminal prohormone of brain natriuretic peptide; EF: ejection fraction.

###### 

In-hospital events and follow-up for patients with normal sUA or hyperuricemia.

                           sUA normal (*n* = 460)   Hyperuricemia (*n* = 251)   *P*
  ------------------------ ------------------------ --------------------------- -------
  *In-hospital events*                                                          
  Heart failure, *n* (%)   68 (15.0)                51 (20.8)                   0.053
  Bleeding, *n* (%)        34 (7.5)                 27 (11.1)                   0.113
  VT, *n* (%)              31 (6.8)                 28 (11.3)                   0.040
  Stroke, *n* (%)          6 (1.3)                  1 (0.4)                     0.244
  Death, *n* (%)           7 (3.7)                  5 (4.8)                     0.642
                                                                                
  *One-year follow-up*                                                          
  Revascularization        6 (1.5)                  5 (2.3)                     0.432
  Readmission, *n* (%)     158 (36.7)               97 (42.7)                   0.129
  Stroke, *n* (%)          24 (5.9)                 7 (3.3)                     0.159
  Bleeding, *n* (%)        294 (68.2)               154 (67.2)                  0.801
  Death, *n* (%)           77 (16.7)                58 (23.1)                   0.039

sUA: serum uric acid; VT: ventricular tachycardia.

###### 

Differences between women and men.

  Parameters                              Women                   Men                     ^*∗*^ *P*                                                                                                               
  --------------------------------------- ----------------------- ----------------------- ------------------------ --------- ------------------------ ------------------------ ------------------------ --------- ---------
  *Demographics and medical history*                                                                                                                                                                              
  Age, years (median, IQR)                78 (76--81)             78 (76--80)             78 (76--81)              0.510     78 (76--80)              78 (76--80)              78 (76--80)              0.455     0.381
  Body mass index (median, IQR)           22.7 (20.6--25.4)       22.8 (20.6--25.1)       22.5 (20.5--26.3         0.644     23.1 (20.9--25.4)        22.8 (20.9--25.5)        23.7 (20.8--26.3)        0.065     0.427
  Diabetes mellitus, *n* (%)              96 (35.2)               57 (34.8)               39 (35.8)                0.862     116 (26.5)               81 (27.4)                35 (24.6)                0.546     0.014
  Hypertension, *n* (%)                   217 (79.5)              126 (76.8)              91 (83.5)                0.182     319 (72.8)               208 (70.3)               111 (78.2)               0.02      0.056
  Atrial fibrillation, *n* (%)            30 (11.2)               16 (9.9)                14 (13.0)                0.440     53 (12.3)                27 (9.2)                 26 (18.7)                0.005     0.656
  CKD ≥3                                  13 (4.8)                3 (1.8)                 10 (9.2)                 0.005     26 (5.9)                 14 (4.7)                 12 (8.5)                 0.125     0.506
  Stroke, *n* (%)                         32 (11.9)               19 (11.8)               13 (12.1)                0.931     71 (16.5)                51 (17.5)                20 (14.5)                0.438     0.098
  Previous chest pain, *n* (%)            181 (67.5)              111 (68.9)              70 (65.4)                0.546     286 (66.2)               188 (64.2)               98 (70.5)                0.193     0.716
  Previous PCI, *n* (%)                   36 (13.5)               24 (15.0)               12 (11.2)                0.375     78 (18.1)                58 (19.8)                20 (14.4)                0.172     0.112
  Previous CABG, *n* (%)                  3 (1.1)                 2 (1.2)                 1 (0.9)                  0.815     10 (2.3)                 7 (2.4)                  3 (2.2)                  0.882     0.255
  Current smoking, *n* (%)                14 (5.4)                7 (4.4)                 7 (6.8)                  0.407     239 (56.5)               164 (57.3)               75 (54.7)                0.614     \<0.001
                                                                                                                                                                                                                  
  *Clinical presentation*                                                                                                                                                                                         
  Hyperuricemia, *n* (%)                  109 (39.9)                                                                         142 (32.4)                                                                           0.042
  Severe heart failure, *n* (%)           155 (56.8)              83 (50.6)               72 (66.1)                0.012     201 (46.0)               120 (40.7)               81 (57.0)                0.001     0.005
  STEMI, *n* (%)                          55 (20.5)               38 (23.6)               17 (15.9)                0.126     119 (27.9)               77 (26.9)                42 (30.0)                0.506     0.028
  NSTE-ACS, *n* (%)                       213 (79.5)              123 (76.4)              90 (84.1)                0.126     307 (72.1)               209 (73.1)               98 (70.0)                0.506     0.028
                                                                                                                                                                                                                  
  *Laboratory data*                                                                                                                                                                                               
  WBC, 10^9^/L (mean ± SD)                7.4 ± 3.3               7.3 ± 3.4               7.5 ± 3.1                0.655     7.2 ± 3.2                7.1 ± 3.2                7.5 ± 3.2                0.287     0.568
  Hemoglobin, g/L (mean ± SD)             110.4 ± 18.3            112.4 ± 16.5            107.3 ± 20.5             0.025     121.8 ± 20.2             123.1 ± 20.0             118.9 ± 21.1             0.039     \<0.001
  Platelets, 10^9^/L (mean ± SD)          202.9 ± 64.9            208.5 ± 64.6            194.7 ± 64.8             0.090     174.3 ± 61.4             117.9 ± 61.4             166.7 ± 61.0             0.080     \<0.001
  Fasting glucose, mmol/l (median, IQR)   6.0 (4.9--7.6)          6.1 (5.0--7.9)          5.9 (4.9--6.9)           0.255     5.7 (4.8--7.1)           5.7 (4.8--7.1)           5.6 (4.8--6.7)           0.467     0.181
  HbA1C, % (median, IQR)                  6.7 (6.0--7.4)          6.5 (5.9--7.5)          6.7 (6.0--7.0)           0.891     6.1 (5.6--6.5)           6.2 (5.7--6.8)           5.8 (5.5--6.2)           0.078     0.005
  ALT, U/l (median, IQR)                  17.5 (11.7--28.3)       17.6 (11.8--28.2)       17.5 (11.5--29.6)        0.932     19.9 (13.6--33.5)        20.2 (13.9--33.2)        19.6 (13.3--34.8)        0.738     0.012
  AST, U/l (median, IQR)                  22.6 (17.1--39.5)       22.0 (16.3--47.0)       22.8 (19.2--36.8)        0.728     22.6 (17.8--49.9)        23.5 (17.8--55.5)        21.5 (17.4--38.0)        0.742     0.579
  Albumin, g/L (mean ± SD)                35.1 ± 4.5              35.1 ± 4.2              35.1 ± 4.8               0.942     35.1 ± 4.1               35.2 ± 3.9               34.9 ± 4.4               0.516     0.902
  Triglycerides, mmol/l (mean ± SD)       1.6 ± 1.0               1.5 ± 0.9               1.7 ± 1.2                0.323     1.6 ± 4.2                1.6 ± 5.1                1.5 ± 1.0                0.740     0.960
  Total cholesterol, mmol/l (mean ± SD)   4.1 ± 1.0               4.1 ± 1.0               4.1 ± 1.1                0.913     3.8 ± 0.9                3.7 ± 0.9                3.8 ± 1.0                0.400     \<0.001
  HDL-cholesterol, mmol/l (mean ± SD)     1.1 ± 0.3               1.1 ± 0.3               1.1 ± 0.3                0.288     1.0 ± 0.3                1.1 ± 0.3                1.0 ± 0.2                0.012     0.002
  LDL-cholesterol, mmol/l (mean ± SD)     2.4 ± 0.9               2.4 ± 0.9               2.5 ± 1.0                0.575     2.2 ± 0.8                2.2 ± 0.8                2.3 ± 0.9                0.373     0.002
  Creatinine, *μ*mol/l (mean ± SD)        89.9 ± 54.1             76.0 ± 35.3             111.1 ± 69.2             \<0.001   124.4 ± 98.6             108.0 ± 78.5             158.3 ± 124.4            \<0.001   \<0.001
  sUA, *μ*mol/l (mean ± SD)               349.2 ± 119.1           274.4 ± 52.0            462.0 ± 101.3            \<0.001   381.4 ± 110.1            322.6 ± 61.9             504.1 ± 84.3             \<0.001   \<0.001
  PT, *s* (mean ± SD)                     13.7 ± 4.3              13.1 ± 1.5              147 ± 6.5                0.100     13.5 ± 2.8               13.4 ± 2.9               13.6 ± 2.4               0.715     0.674
  APTT, *s* (mean ± SD)                   39.5 ± 14.4             40.1 ± 15.5             38.5 ± 12.8              0.667     41.4 ± 22.2              43.5 ± 24.7              35.4 ± 11.1              0.109     0.562
  CK-Mb, U/l (mean ± SD)                  35.0 ± 71.4             37.6 ± 81.5             30.9 ± 52.3              0.475     44.3 ± 119.0             44.4 ± 113.0             44.1 ± 131.1             0.982     0.266
  TnT, pg/ml (median, IQR)                19.3 (9.7--603.3)       16.9 (9.5--847.0)       27.8 (9.0--603.3)        0.819     33.2 (12.3--1461.0)      21.4 (11.6--1305.5)      56.0 (13.6--3185.8)      0.290     0.141
  hs-CRP, mg/l (median, IQR)              4.3 (1.3--23.2)         4.3 (1.2--25.5)         5.3 (1.6--20.7)          0.967     5.1 (1.4--20.2)          4.2 (1.2--20.8)          7.5 (2.2--20.1)          0.076     0.849
  NT-proBNP, pg/ml (median, IQR)          935.9 (290.4--3082.5)   718.0 (255.5--1999.1)   1619.2 (433.1--5058.7)   0.001     1337.0 (394.9--3737.7)   1037.0 (321.5--2917.2)   2055.0 (618.1--5153.8)   0.001     0.067
  EF, % (mean ± SD)                       53 ± 10.4               55 ± 9.2                51.6 ± 11.7              0.009     53 ± 10.9                53 ± 1.05                53 ± 11.9                0.754     0.460
                                                                                                                                                                                                                  
  *In-hospital management*                                                                                                                                                                                        
  Aspirin, *n* (%)                        227 (83.2)              141 (86.0)              86 (78.9)                0.126     376 (86.2)               265 (89.9)               111 (78.2)               0.001     0.262
  Clopidogrel, *n* (%)                    234 (86.0)              141 (86.0)              93 (86.1)                0.975     391 (89.5)               266 (90.1)               125 (88.7)               0.699     0.168
  ACEI/ARB, *n* (%)                       168 (61.5)              105 (64.0)              63 (57.8)                0.300     268 (61.2)               189 (63.9)               79 (55.6)                0.099     0.925
  Beta blocker, *n* (%)                   206 (75.5)              123 (75.0)              83 (76.1)                0.829     306 (69.9)               207 (69.9)               99 (69.7)                0.964     0.106
  Statin, *n* (%)                         265 (97.8)              157 (96.9)              108 (99.1)               0.234     422 (96.3)               288 (97.3)               134 (94.4)               0.126     0.283
  Diuretic, *n* (%)                       128 (47.6)              67 (41.6)               61 (56.5)                0.017     210 (48.6)               133 (45.4)               77 (55.4)                0.052     0.791
  PPI, *n* (%)                            227 (84.4)              133 (82.6)              94 (87.0)                0.327     340 (78.7)               230 (78.5)               110 (79.1)               0.880     0.063
  IABP, *n* (%)                           7 (2.6)                 3 (1.9)                 4 (3.7)                  0.353     18 (4.2)                 12 (4.1)                 6 (4.4)                  0.890     0.255
                                                                                                                                                                                                                  
  *In-hospital events*                                                                                                                                                                                            
  Heart failure, *n* (%)                  42 (15.7)               22 (13.7)               20 (18.9)                0.253     77 (17.9)                46 (15.8)                31 (22.3)                0.100     0.458
  Bleeding, *n* (%)                       22 (8.2)                11 (6.8)                11 (10.4)                0.303     39 (9.1)                 23 (7.9)                 16 (11.6)                0.210     0.706
  VT, *n* (%)                             23 (8.6)                10 (6.2)                13 (12.0)                0.094     36 (8.3)                 21 (7.2)                 15 (10.8)                0.203     0.920
  Stroke, *n* (%)                         5 (1.9)                 4 (2.5)                 1 (0.9)                  0.354     2 (0.5)                  2 (0.7)                  0 (0.0)                  0.329     0.071
  Death, *n* (%)                          4 (3.5)                 1 (1.4)                 3 (7.0)                  0.119     8 (4.4)                  6 (5.0)                  2 (3.3)                  0.587     0.693
                                                                                                                                                                                                                  
  *One-year follow-up*                                                                                                                                                                                            
  Revascularization                       4 (1.6)                 1 (0.6)                 3 (3.2)                  0.120     7 (1.9)                  5 (2.0)                  2 (1.7)                  0.841     0.801
  Readmission, *n* (%)                    96 (36.9)               57 (35.8)               39 (38.6)                0.653     159 (39.9)               101 (37.1)               58 (46.0)                0.092     0.436
  Stroke, *n* (%)                         13 (5.2)                7 (4.5)                 6 (6.4)                  0.513     18 (4.8)                 17 (6.7)                 1 (0.8)                  0.013     0.827
  Bleeding, *n* (%)                       180 (69.2)              109 (69.0)              71 (69.6)                0.916     268 (67.0)               185 (67.8)               83 (65.4)                0.633     0.549
  Death, *n* (%)                          40 (14.7)               16 (9.8)                24 (22.0)                0.005     95 (21.7)                61 (20.6)                34 (32.4)                0.428     0.020

sUA: serum uric acid; IQR: interquartile range; CKD: chronic kidney disease; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; SBP: systolic blood pressure; DBP: diastolic blood pressure; STEMI: ST-elevated myocardial infarction; NSTE-ACS: non-ST-elevation acute coronary syndrome; WBC: white blood cells; HbA1c: glycated hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; HDL: high-density lipoprotein; LDL: low-density lipoprotein; PT: prothrombin time; APTT: activated prothrombin time; CK: creatine kinase; CK-Mb: creatine kinase Mb chain; TnT: troponin *T*; hs-CRP: high-sensitivity C-reactive protein; NR-proBNP: N-terminal prohormone of brain natriuretic peptide; EF: ejection fraction; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; PPI: proton pump inhibitor; IABP: intra-aortic balloon pump; VT: ventricular tachycardia.
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